Skip to main content
Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
7.92
-0.15 (-1.86%)
At close: Apr 28, 2026, 4:00 PM EDT
7.97
+0.05 (0.63%)
After-hours: Apr 28, 2026, 7:59 PM EDT

Novavax Revenue

In the year 2025, Novavax had annual revenue of $1.12B with 64.69% growth. Novavax had revenue of $147.14M in the quarter ending December 31, 2025, with 66.61% growth.

Revenue (ttm)
$1.12B
Revenue Growth
+64.69%
P/S Ratio
1.15
Revenue / Employee
$1,499,972
Employees
749
Market Cap
1.29B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20251.12B441.32M64.69%
Dec 31, 2024682.16M-301.54M-30.65%
Dec 31, 2023983.71M-998.17M-50.36%
Dec 31, 20221.98B835.58M72.89%
Dec 31, 20211.15B670.69M141.02%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Iovance Biotherapeutics 263.50M
AbCellera Biologics 75.13M
Viridian Therapeutics 70.85M
Wave Life Sciences 42.73M
Maze Therapeutics 2.50M
Revenue Rankings

NVAX News

More News